GlobeNewswire

Stryker announces intention to nominate Jim Davis to board of directors
09/11/2026
Portage, MI, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Stryker announces intention to nominate Jim Davis to board of directors Stryker (NYSE:SYK) announced that its board of directors has nominated Jim Davis for election to the [...]
PetMeds Announces Strategic Partnership with Pet Supermarket to Expand Pharmacy Offering Across Retail and Digital Channels
09/11/2026
DELRAY BEACH, Fla., Nov. 09, 2026 (GLOBE NEWSWIRE) -- PetMed Express, Inc., dba PetMeds and parent company of PetCareRx (Nasdaq: PETS), today announced a new partnership with Pet Supermarket to offer pet prescription [...]
Apollomics Reports First-Half 2026 Financial Results
09/11/2026
Phase 2 studies ongoing to advance global development of vebreltinib, a highly potent, de-risked and differentiated c-MET Inhibitor with best-in-class and first-in-class potential. FOSTER CITY, Calif., Nov. 09, 2026 ( [...]
ImageneBio Reports Third Quarter 2026 Financial Results
09/11/2026
SAN DIEGO, Nov. 09, 2026 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (Nasdaq: IMA) (“Imagene” or the “Company”) today reported financial results for the quarter ended September 30, 2026, and provided a company update. Company [...]
Trevi Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Updates
09/11/2026
Initiated Phase 3 OCEAN-2 trial for patients with IPF-related chronic cough in the third quarter; both Phase 3 OCEAN trials actively recruiting Positive meeting with the FDA on the non-IPF ILD-related chronic cough [...]
Oruka Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
09/11/2026
EVERLAST-B Week 16 results showed 61% PASI 100 and 86% PASI 90 in the ORKA-001 high-dose group, highly consistent with EVERLAST-A EVERLAST-A responses continued to deepen to 71% PASI 100 at Week 28, 6 months after last [...]
Globus Medical to Participate in Jefferies Global Healthcare Conference
09/11/2026
AUDUBON, Pa., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, today announced it is scheduled to participate in the Jefferies Global Healthcare [...]
SodaPeak Launch 2026 Advanced Soda Peak Gummies for Male Vitality and Energy Supplement New Information For Multi-Ingredient And Benefits.
09/11/2026
SodaPeak introduces Soda Peak Gummies in the USA, a multi-ingredient dietary supplement formulated for male vitality and energy wellness, with details on ingredients, product features and usage information. New York, [...]
Altimmune Presents Positive Late-Breaking Pemvidutide Data at AASLD The Liver Meeting® 2026 in Patients with Alcohol Use Disorder
09/11/2026
Results from RECLAIM Phase 2 study show treatment with pemvidutide led to significant reduction in heavy drinking days and improved outcomes on other key clinical measures in patients with AUD; generally favorable [...]
Solana Company to Release Third Quarter 2026 Operating Results on November 11, 2026
09/11/2026
PHILADELPHIA, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Solana Company (NASDAQ: HSDT) (the “Company” or “HSDT”), a publicly listed digital asset treasury, infrastructure, and services company providing institutional access to [...]
Zealand Pharma to participate in the Jefferies Global Healthcare Conference
09/11/2026
Press release – No. 23 / 2026 Zealand Pharma to participate in the Jefferies Global Healthcare Conference Copenhagen, Denmark, November 9, 2026 - Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology [...]
Kyverna Therapeutics Announces Publication of Registrational Miv-cel Data in Patients with Stiff Person Syndrome in JAMA Neurology
09/11/2026
Publication reinforces miv-cel's potential to deliver durable clinical benefit with a single dose, enabled by miv-cel's unique construct, and become the first approved therapy in SPS and first approved CAR T-cell [...]
Hinge Bio Shares Encouraging Clinical Data for HB2198, a Novel B-Cell Depleting Agent for Treating Autoimmune Disease, at ACR Convergence 2026
09/11/2026
Encouraging safety and pharmacodynamic activity observed with HB2198 in normal healthy volunteers was presented with additional preclinical data at the American College of Rheumatology (ACR) Convergence 2026 REDWOOD [...]
NTG Nordic Transport Group publishes interim report for Q3 2026
09/11/2026
Company announcement no. 47 – 26 09 November 2026 NTG Nordic Transport Group publishes interim report for Q3 2026 The interim report for Q3 2026 is enclosed. In connection with publication of the results for Q3 2026, a [...]
NTG Nordic Transport Group A/S – Launch of medium-term financial targets for 2029-2031
09/11/2026
Company announcement no. 46 – 26 09 November 2026 NTG Nordic Transport Group A/S – Launch of medium-term financial targets for 2029-2031 NTG Nordic Transport Group A/S (“NTG”) today launches medium-term financial [...]
Baylor Genetics to Highlight the Clinical Value of Genomics in Pediatric Care at the 2026 National Society of Genetic Counselors Annual Meeting
09/11/2026
Two new data presentations underscore the diagnostic and clinical utility of genome and exome sequencing for pediatric patients with hearing loss and immunodeficiency HOUSTON, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Baylor [...]
Cullinan Therapeutics to Participate in Upcoming Investor Conferences
09/11/2026
CAMBRIDGE, Mass., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, disease-modifying T [...]
Kraig Labs Ships Spider Silk to Developers Across Global Industries
09/11/2026
A Global Apparel Pilot and Shipment to a Materials Innovator with Aerospace Experience Put Customer Feedback in Focus DENVER, Nov. 09, 2026 (GLOBE NEWSWIRE) -- ( 247MarketNews )—Kraig Biocraft Laboratories ( OTCQB: KBLB [...]
Zealand Pharma announces Boehringer Ingelheim’s survodutide is the first glucagon/GLP-1 dual agonist to demonstrate a favorable cardiovascular safety profile in global Phase 3 SYNCHRONIZE-CVOT trial with significant cardiometabolic benefits
09/11/2026
Company announcement – No. 55 / 2026 Zealand Pharma announces Boehringer Ingelheim’s survodutide is the first glucagon/GLP-1 dual agonist to demonstrate a favorable cardiovascular safety profile in global Phase 3 [...]

Pages

Other news

Test 2

Lorem ipsum

Test 1

Lorem upsum